Michael Donovan Ph.D., M.D. joined Vigilant Biosciences in 2015 and serves as the Chief Medical Officer. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid–based assays and coupled mathematical applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Along with his clinical duties, Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York.
In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. where he served as laboratory director and was responsible for the implementation and execution of several clinical trials.
Dr. Donovan earned a B.S. in Zoology from Rutgers University, a Master of Science in Endocrinology and a Ph.D. in Cell and Developmental Biology with Post–Doctoral studies at Harvard Medical School. He earned his M.D. from the University of Medicine and Dentistry of New Jersey.